Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTN4HXA2)

• DOT Name: Lymphocyte antigen 96 (LY96)
• Synonyms: Ly-96; ESOP-1; Protein MD-2
• Gene Name: LY96
• UniProt ID: LY96_HUMAN
• PDB ID: 2E56; 2E59; 2Z65; 3FXI; 3ULA; 4G8A
• Pfam ID: PF02221
• Sequence:
  MLPFLFFSTLFSSIFTEAQKQYWVCNSSDASISYTYCDKMQYPISINVNPCIELKRSKGL
  LHIFYIPRRDLKQLYFNLYITVNTMNLPKRKEVICRGSDDDYSFCRALKGETVNTTISFS
  FKGIKFSKGKYKCVVEAISGSPEEMLFCLEFVILHQPNSN
• Function: Binds bacterial lipopolysaccharide (LPS). Cooperates with TLR4 in the innate immune response to bacterial lipopolysaccharide (LPS), and with TLR2 in the response to cell wall components from Gram-positive and Gram-negative bacteria. Enhances TLR4-dependent activation of NF-kappa-B. Cells expressing both LY96 and TLR4, but not TLR4 alone, respond to LPS.
• KEGG Pathway:
  NF-kappa B sig.ling pathway (hsa04064)
  Toll-like receptor sig.ling pathway (hsa04620)
  Alcoholic liver disease (hsa04936)
  Salmonella infection (hsa05132)
  Pertussis (hsa05133)
  Toxoplasmosis (hsa05145)
  Lipid and atherosclerosis (hsa05417)
• Reactome Pathway:
  Caspase activation via Death Receptors in the presence of ligand (R-HSA-140534)
  Toll Like Receptor 4 (TLR4) Cascade (R-HSA-166016)
  MyD88 (R-HSA-166058)
  MyD88-independent TLR4 cascade (R-HSA-166166)
  TRIF-mediated programmed cell death (R-HSA-2562578)
  MyD88 deficiency (TLR2/4) (R-HSA-5602498)
  IRAK4 deficiency (TLR2/4) (R-HSA-5603041)
  Regulation of TLR by endogenous ligand (R-HSA-5686938)
  Activation of IRF3, IRF7 mediated by TBK1, IKK (IKBKE) (R-HSA-936964)
  IKK complex recruitment mediated by RIP1 (R-HSA-937041)
  TRAF6-mediated induction of TAK1 complex within TLR4 complex (R-HSA-937072)
  Heme signaling (R-HSA-9707616)
  IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation (R-HSA-975163)
  ER-Phagosome pathway (R-HSA-1236974)

Molecular Interaction Atlas (MIA) of This DOT

26 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate decreases the expression of Lymphocyte antigen 96 (LY96).	[1]
Ciclosporin	DMAZJFX	Approved	Ciclosporin increases the expression of Lymphocyte antigen 96 (LY96).	[2]
Acetaminophen	DMUIE76	Approved	Acetaminophen decreases the expression of Lymphocyte antigen 96 (LY96).	[3]
Doxorubicin	DMVP5YE	Approved	Doxorubicin decreases the expression of Lymphocyte antigen 96 (LY96).	[4]
Cupric Sulfate	DMP0NFQ	Approved	Cupric Sulfate increases the expression of Lymphocyte antigen 96 (LY96).	[5]
Quercetin	DM3NC4M	Approved	Quercetin increases the expression of Lymphocyte antigen 96 (LY96).	[6]
Temozolomide	DMKECZD	Approved	Temozolomide decreases the expression of Lymphocyte antigen 96 (LY96).	[7]
Arsenic trioxide	DM61TA4	Approved	Arsenic trioxide increases the expression of Lymphocyte antigen 96 (LY96).	[8]
Hydrogen peroxide	DM1NG5W	Approved	Hydrogen peroxide increases the expression of Lymphocyte antigen 96 (LY96).	[9]
Calcitriol	DM8ZVJ7	Approved	Calcitriol increases the expression of Lymphocyte antigen 96 (LY96).	[10]
Testosterone	DM7HUNW	Approved	Testosterone increases the expression of Lymphocyte antigen 96 (LY96).	[10]
Triclosan	DMZUR4N	Approved	Triclosan decreases the expression of Lymphocyte antigen 96 (LY96).	[11]
Methotrexate	DM2TEOL	Approved	Methotrexate decreases the expression of Lymphocyte antigen 96 (LY96).	[12]
Folic acid	DMEMBJC	Approved	Folic acid increases the expression of Lymphocyte antigen 96 (LY96).	[13]
Demecolcine	DMCZQGK	Approved	Demecolcine increases the expression of Lymphocyte antigen 96 (LY96).	[14]
Cannabidiol	DM0659E	Approved	Cannabidiol decreases the expression of Lymphocyte antigen 96 (LY96).	[15]
Troglitazone	DM3VFPD	Approved	Troglitazone increases the expression of Lymphocyte antigen 96 (LY96).	[16]
Hydroquinone	DM6AVR4	Approved	Hydroquinone increases the expression of Lymphocyte antigen 96 (LY96).	[17]
Azathioprine	DMMZSXQ	Approved	Azathioprine increases the expression of Lymphocyte antigen 96 (LY96).	[18]
Methamphetamine	DMPM4SK	Approved	Methamphetamine increases the expression of Lymphocyte antigen 96 (LY96).	[19]
Prednisolone	DMQ8FR2	Approved	Prednisolone decreases the expression of Lymphocyte antigen 96 (LY96).	[20]
Diphenylpyraline	DMW4X37	Approved	Diphenylpyraline decreases the expression of Lymphocyte antigen 96 (LY96).	[21]
Adenosine	DMM2NSK	Approved	Adenosine increases the expression of Lymphocyte antigen 96 (LY96).	[22]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A increases the expression of Lymphocyte antigen 96 (LY96).	[24]
Formaldehyde	DM7Q6M0	Investigative	Formaldehyde increases the expression of Lymphocyte antigen 96 (LY96).	[14]
Paraquat	DMR8O3X	Investigative	Paraquat increases the expression of Lymphocyte antigen 96 (LY96).	[25]

1 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene increases the methylation of Lymphocyte antigen 96 (LY96).	[23]

References

• [1] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [2] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [3] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [4] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [5] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [6] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [7] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [8] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [9] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [10] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [11] Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021 Oct 12;22(20):11005. doi: 10.3390/ijms222011005.
• [12] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [13] Folic acid modulates cancer-associated micro RNAs and inflammatory mediators in neoplastic and non-neoplastic colonic cells in a different way. Mol Nutr Food Res. 2017 Dec;61(12). doi: 10.1002/mnfr.201700260. Epub 2017 Nov 9.
• [14] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [15] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [16] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [17] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [18] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [19] Methamphetamine alters the normal progression by inducing cell cycle arrest in astrocytes. PLoS One. 2014 Oct 7;9(10):e109603.
• [20] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [21] Controlled diesel exhaust and allergen coexposure modulates microRNA and gene expression in humans: Effects on inflammatory lung markers. J Allergy Clin Immunol. 2016 Dec;138(6):1690-1700. doi: 10.1016/j.jaci.2016.02.038. Epub 2016 Apr 24.
• [22] Adenosine reduces cell surface expression of toll-like receptor 4 and inflammation in response to lipopolysaccharide and matrix products. J Cardiovasc Transl Res. 2011 Dec;4(6):790-800. doi: 10.1007/s12265-011-9279-x. Epub 2011 May 3.
• [23] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [24] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [25] CD34+ derived macrophage and dendritic cells display differential responses to paraquat. Toxicol In Vitro. 2021 Sep;75:105198. doi: 10.1016/j.tiv.2021.105198. Epub 2021 Jun 9.